CALCA and medullary thyroid gland carcinoma: Dulaglutide, a once-weekly long-acting GLP-1RA, did not affect serum calcitonin levels during a 6-month follow-up of 56-year-old women with preexisting elevation of serum calcitonin and medullary thyroid carcinoma.